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Objectives The purpose of the study was to assess the cardiovascular risk of impaired fasting glucose (IFG).
Background The associations between IFG, incident type 2 diabetes mellitus (T2DM), and cardiovascular (CV) events remains
unclear.
Methods The MESA (Multi-Ethnic Study of Atherosclerosis) study included participants who were 45 to 84 years or age
and free of clinical CV disease at baseline (2000 to 2002). Type 2 DM was defined as fasting glucose 125
mg/dl or receiving antidiabetes medication at baseline and follow-up examinations; IFG was defined as no
T2DM and fasting glucose 100 to 125 mg/dl. Cox proportional hazards analysis was used to assess the associa-
tion between IFG and incident DM and also between IFG and incident CV events.
Results Of 6,753 participants included in these analyses, 840 (12.7%) had T2DM and 940 (13.8%) had IFG at the base-
line examination. During 7.5 years of follow-up, there were 418 adjudicated CV events. Type 2 DM was associ-
ated with an increased CV incidence in the univariate model (hazard ratio [HR]: 2.83, 95% confidence interval
[CI]: 2.25 to 3.56, p  0.0001) and multivariate model adjusted for demographics and traditional risk factors
(HR: 1.87, 95% CI: 1.47 to 2.37, p  0.0001) compared with subjects not having T2DM (IFG plus normal fasting
glucose). Impaired fasting glucose was associated with increased incidence of T2DM (HR: 13.2, 95% CI: 10.8 to
16.2, p  0.001) that remained after adjusting for demographics, highest educational level, physical activity,
and body mass index (HR: 10.5, 95% CI: 8.4 to 13.1, p  0.001) compared with normal fasting glucose. Im-
paired fasting glucose was associated with incident CV events in the univariate model (HR: 1.64, 95% CI: 1.26 to
2.14, p  0.001) but not in the full multivariate model (HR: 1.16, 95% CI: 0.88 to 1.52, p  0.3) compared with
normal fasting glucose.
Conclusions Having IFG was not independently associated with an increased short-term risk for incident CV events. These
data reiterate the importance of intervention for persons with IFG to reduce their incidence of T2DM. (J Am
Coll Cardiol 2011;58:140–6) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.025It has been estimated that 44 million adults in the United
States have impaired fasting blood glucose (IFG), and the
numbers will likely continue to increase as a consequence of
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accepted March 22, 2011.the ongoing obesity epidemic (1,2). Persons with IFG
(pre-diabetes) are at an increased risk of having type 2
diabetes mellitus (T2DM) develop compared with subjects
with normal fasting glucose (NFG) (3,4). However, the
relationship between IFG and clinical cardiovascular (CV)
events is less well established, with some but not all studies
suggesting that IFG is an independent cardiovascular dis-
ease (CVD) risk factor. Furthermore, the currently available
data concerning IFG and CV events are from cohorts with
established CVD (5–7) and/or from either single sex or
race/ethnicity groups (8–12), limiting their applicability to
general populations.
Several meta-analyses have attempted to address this ques-
tion but these meta-analyses have limitations, such as single
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July 5, 2011:140–6 IFG, Incident Type 2 DM, and CVD Events in Adultsrace/ethnicity, the use of International Classification of
Disease-Ninth Revision (ICD-9) codes, significant loss to
follow-up of participants, and differences in the constituents
of the composite outcomes in the studies that were included
in these meta-analyses (13–15). Moreover, the degree of
adjustment for potential confounders in the studies included
in these meta-analyses was variable, limiting the validity of
the direct comparison of risk in these studies (13–15). Some of
the studies included in these meta-analysis had follow-up
periods as long as 21 years, a period by which most persons
with impaired fasting glucose would have had diabetes
mellitus (DM) develop for at least 10 years, making it
unclear whether this increased CV risk was due to DM or to
IFG (13,14).
To clarify the associations of IFG with both T2DM and
CVD in a more ethnically diverse population, we examined
baseline IFG and 7.5-year incident T2DM and CV events
in the MESA (Multi-Ethnic Study of Atherosclerosis)
study.
Methods
Study population and data collection. The study design
for the MESA study has been published elsewhere (16). In
brief, the MESA study is a prospective cohort study to
investigate the prevalence, correlates, and progression of
subclinical CVD in persons without known CVD at base-
line. The cohort includes 6,814 women and men ages 45 to
84 years recruited from 6 U.S. communities (Baltimore,
Maryland; Chicago, Illinois; Forsyth County, North Caro-
lina; Los Angeles County, California; northern Manhattan,
New York; and St. Paul, Minnesota). The MESA cohort
participants were 38% white, 28% African American, 22%
Hispanic, and 12% Chinese. Persons with a history of
physician-diagnosed myocardial infarction, angina, heart
failure, stroke, or transient ischemic attack, or who had
undergone an invasive procedure for CVD (coronary artery
bypass graft surgery, angioplasty, valve replacement, pace-
maker placement, or other vascular surgeries) were excluded
from participation. This study was approved by the institu-
tional review boards of each study site, and written informed
consent was obtained from all participants.
Demographics, medical history, and anthropometric and
laboratory data for the present study were taken from the
first examination of the MESA cohort (July 2000 to August
2002). Current smoking was defined as having smoked a
cigarette in the last 30 days. Use of antihypertensive and
other medications was based on review of prescribed med-
ication containers. Resting blood pressure was measured 3
times in the seated position, and the average of the second
and third readings was recorded. Hypertension was defined
as a systolic blood pressure 140 mm Hg, diastolic blood
pressure 90 mm Hg, or use of medication prescribed for
hypertension. Body mass index was calculated as weight
(kg) divided by height (m2). Total cholesterol and high-ensity lipoprotein cholesterol were measured from blood Camples obtained after a 12-h fast.
ow-density lipoprotein choles-
erol was estimated by the Friede-
ald equation (17). Fasting blood
lucose (serum) was measured by
he glucose oxidase method on the
itros analyzer (Johnson & John-
on Clinical Diagnostics, Roches-
er, New York).
Diabetes mellitus was defined
s fasting glucose 125 mg/dl or
he use of hypoglycemic medica-
ions. Among subjects not re-
orting use of hypoglycemic
edications, we defined IFG as
etween 100 and 125 mg/dl and
FG as 100 mg/dl.
efinition of incident DM. Fasting blood glucose was
easured, and data on the use of diabetes medication were
ollected from the MESA study participants during exam-
nations 2, 3, and 4 (follow-up through 2007). Incident
2DM in the present study was defined as fasting blood
lucose 125 mg/dl or use of hypoglycemic medications
uring examinations 2, 3, or 4 of participants who did not
ave T2DM during the baseline MESA study examination
2000 to 2002).
scertainment of CV events. Cardiovascular events were
djudicated by a MESA study committee that included
ardiologists, physician epidemiologists, and neurologists. A
etailed description of the CV event adjudication process
as already been published (21). For the purposes of this
tudy, we define our composite outcome (composite event)
s incident myocardial infarction, definite angina, probable
ngina (if followed by coronary artery bypass grafting and
ercutaneous coronary intervention), resuscitated cardiac
rrest, stroke, stroke death, coronary heart disease death, or
ther CVD death as defined by the MESA protocol.
tatistical analysis. Descriptive data are presented as mean
D for continuous variables or the frequencies of partici-
ants for categorical variables. Kaplan-Meier analysis was
sed to assess the univariate association of the 3 categories
f glucose control (NFG, IFG, and T2DM) with incident
V events. Cox proportional hazards regression model was
se to assess the association of: 1) fasting blood glucose (as
continuous variable) with incident CV event; 2) DM
compared with subjects not having T2DM) with incident
V events; and 3) IFG (compared with NFG) with incident
V events in both the univariate analysis and multivariable
nalysis, adjusting for confounders including age, sex, race/
thnicity, systolic blood pressure, body mass index (BMI),
igarette smoking, total cholesterol, high-density lipopro-
ein cholesterol, triglycerides, blood pressure medications
se, and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG–
oA) reductase inhibitors use. Potential confounders were
elected on the basis of prior evidence of an association with
Abbreviations
and Acronyms
BMI  body mass index
CI  confidence interval
CV  cardiovascular
CVD  cardiovascular
disease
DM  diabetes mellitus
HR  hazard ratio
IFG  impaired fasting
glucose
NFG  normal fasting
glucose
T2DM  type 2 diabetes
mellitusV events from previous studies. The association between
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IFG, Incident Type 2 DM, and CVD Events in Adults July 5, 2011:140–6IFG (compared with NFG) and the components of our
composite outcome and all cause mortality was also
assessed.
Cox proportional hazards analysis was also used to assess
the association between IFG (compared with normoglyce-
mia) and incidence of DM in a univariate analysis and also
in a multivariate analysis adjusting for age, sex, race/
ethnicity, BMI, physical activity, and educational level.
Finally, traditional CV risk factor profiles and incident CV
event rates of the subcohort with IFG at baseline in whom
T2DM developed and those in whom it did not were
compared. A 2-tailed value of p  0.05 was considered
significant. All statistical analyses were performed using
SAS version 9.2.2 (SAS Institute, Cary, North Carolina).
Results
Twenty-nine participants had missing data on fasting blood
glucose, and 32 participants had no follow-up information,
resulting in a final sample of 6,753 (840 with T2DM, 940
with IFG, and 4,973 with NFG). The mean age of the
cohort was 62.2 years; 52.9% were female; 38.4% were
Caucasian, 11.8% Chinese, 27.8% African American, and
22% Hispanic. Table 1 shows the demographic character-
stics of the 3 fasting blood glucose categories in the MESA
ohort. Subjects with NFG were relatively younger and
Demographic Characteristics of Subjects With Diabetes Mellitus, Iand No mal Fasting Glucose in the MESA StudyTable 1 Demo raph c Characteristics of Subjects With D abeteand Normal Fasting Glucose in the MESA Study
Variable Normoglycemia (n  4,973) Impaire
Age, yrs 61.3 10.3
Male 44.6
Race/ethnicity
Caucasian 43.4
Chinese 11.2
African American 25.5
Hispanic 19.9
Body mass index, kg/m2 27.6 5.2
Cigarette smoking
Never 50.5
Former 36.3
Current 13.2
Systolic BP, mm Hg 124.5 21.2
Diastolic BP, mm Hg 71.5 10.1
Cholesterol, mg/dl
Total 195.1 35.0
LDL 117.9 31.1
HDL 52.5 15.2
Triglycerides 123.3 73.8
BP medication use 31.1
Statin use 12.6
Fasting glucose, mg/dl 86.2 7.0
Highest educational level
Less than high school 14.9
High school 17.7
More than high school 67.4Values are mean  SD or %.
BP  blood pressure; HDL  high-density lipoprotein; LDL  low-density lipoprotein; MESA  Multi-Ethenerally had a better CV risk profile compared with
ubjects having either IFG or T2DM. There were 418
djudicated CV events during the 7.5 years of follow-up:
05 in the DM group, 72 in the IFG group, and 241 in the
FG group.
ssociation of fasting blood glucose and incident CV events.
asting blood glucose was associated with incident CV
vents in both the univariate and the multivariate analysis
hazard ratio [HR] per 10 mg/dl increase: 1.08, 95%
onfidence interval [CI]: 1.06 to 1.10, p 0.0001; and HR:
.05, 95% CI: 1.03 to 1.08, p  0.0001, respectively; data
ot shown). Figure 1 is the Kaplan-Meier adjusted curves
howing comparison of the event-free survival rates of
ubjects with NFG, IFG, and DM in the MESA cohort
95.2%, 92.6%, and 87.5%, respectively; log-rank p 
.0001).
Diabetes mellitus was associated with incident CV events
n both the univariate and multivariate models when com-
ared with subjects without DM (IFG plus NFG [HR:
.58, 95% CI: 2.07 to 3.22; p 0.0001; and HR: 1.87, 95%
I: 1.47 to 2.37, p  0.0001]), respectively (data not
hown).
FG and incidence of DM. A total of 410 participants
ithout DM at baseline had DM during the 7 years of
ollow-up. Compared with NFG, IFG was associated with
ed Fasting Glucose,llitus, Impaired Fasting Glucose,
ing Glucose (n  940) Diabetes Mellitus (n  840) p Value
4.2 9.8 64.7 9.4 0.001
56.0 52.4 0.001
0.001
31.0 18.6
14.5 12.3
29.7 38.4
24.9 30.7
0.1 5.7 30.6 5.8 0.001
0.85
49.8 49.8
37.9 37.4
12.3 12.8
2.0 21.2 133.1 22.1 0.001
4.2 10.6 72.0 10.3 0.001
4.5 35.2 188.5 40.0 0.001
8.3 31.1 111.9 33.7 0.001
7.2 12.7 46.0 12.7 0.001
7.2 91.7 163.1 142.1 0.001
56.1 64.0 0.001
16.8 26.0 0.001
7.8 7.0 151.6 56.4 0.001
24.0 29.7
19.4 20.0
56.6 50.3mpairs Me
d Fast
6
3
13
7
19
11
4
14
10nic Study of Atherosclerosis.
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July 5, 2011:140–6 IFG, Incident Type 2 DM, and CVD Events in Adultsan increased incidence of DM in the univariate analysis
(HR: 13.2, 95% CI: 10.7 to 16.2, p  0.0001) and after
adjusting for age, sex, race/ethnicity, BMI, physical activity,
and measures of socioeconomic status such as highest
educational level (HR: 11.5, 95% CI: 9.3 to 14.3; p 
0.0001), and in the full multivariate model (HR: 10.5, 95%
CI: 8.4 to 13.1, p  0.0001) (Fig. 2).
IFG and incident CV events. Compared with NFG,
IFG was associated with incident CV events in the
univariate analysis (HR: 1.64, 95% CI: 1.26 to 2.14, p 
Figure 1 CV Event-Free Survival of the MESA Study Cohort
Kaplan-Meier curves showing the cardiovascular (CV) event-free survival of particip
pre-diabetes or impaired fasting glucose (IFG) (green line), and normoglycemic (bl
Figure 2 Risk for Incident Diabetes Mellitus
in the MESA Study
Hazard ratio and 95% confidence interval (CI) of IFG compared with normoglyce-
mia for incident diabetes mellitus in Cox proportional hazards models. Model
1: IFGs versus normoglycemics. Model 2: Model 1  age, sex, race/ethnicity,
physical activity, and highest educational level. Model 3: Model 2  body
mass index. Abbreviations as in Figure 1.0.001) and after adjusting for age, sex, race/ethnicity
(HR: 1.31, 95% CI: 1.00 to 1.72, p  0.03). The
ssociation was attenuated in the full multivariate model
HR: 1.16, 95% CI: 0.88 to 1.52, p  0.3) (Fig. 3).
imilar HRs and 95% CIs were obtained when individual
V outcomes and all-cause mortality were evaluated
Table 2). Impaired fasting glucose was not associated
ith incident CV events in any sex or race/ethnicity
ategorized as diabetes mellitus (red line),
) in the MESA (Multi-Ethnic Study of Atherosclerosis) study.
Figure 3 Risk for Incident CV Events in the MESA Study
Hazard ratio and 95% CI of IFG compared with normoglycemia for incident car-
diovascular (CV) event in the stepwise Cox proportional hazards models. Model
1: IFGs versus normoglycemics. Model 2: Model 1  age, sex, and race/eth-
nicity. Model 3: Model 2  body mass index. Model 4: Model 3  cigarette
smoking status, systolic blood pressure, total cholesterol, high-density lipopro-
tein, triglycerides, blood pressure medication, and statin medication use.
Abbreviations as in Figures 1 and 2.ants c
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IFG, Incident Type 2 DM, and CVD Events in Adults July 5, 2011:140–6group when our full multivariable model was stratified by
sex or race/ethnicity (data not shown).
Subjects with IFG who had T2DM and incident CV
events. Diabetes mellitus developed in 273 participants
with IFG during the follow-up period. When compared
with IFG patients who did not have DM during
follow-up (n  600), these participants were younger,
ore likely female, with higher BMI. Variables such as
ge, lipid profiles, systolic blood pressure, Framingham
isk score, race/ethnicity, educational level, and smoking
tatus were not significantly different between these
roups (Table 3). Compared with subjects with IFG who
id not have DM develop, subjects who did have T2DM
evelop during the follow-up period had higher incident
V events in the univariate model (HR: 1.65, 95% CI:
.04 to 2.62, p  0.03) but not in our full multivariable
odel (HR: 1.25, 95% CI: 0.78 to 1.99, p  0.35).
imilarly, participants with normal glucose at baseline
NFG) who had DM during follow-up did not have a
Hazard Ratio of Impaired Fasting Glucose CompNormoglycemia for the Primary Outcome of CardEvents and Individu l Ca diovasc lar Di ase O
Table 2
H zard Ratio of Impaired Fasting G
Normoglycemia for the Primary Out
Events and Individual Cardiovascula
Outcome
No. of
Events
Univariate Mode
(95% CI)
Composite 418 1.64 (1.26–2.14)
Hard CHD 283 1.41 (1.01–1.97)
MI 183 1.57 (1.00–2.48)
Stroke 114 1.22 (0.69–2.13)
Angina 211 1.95 (1.36–2.81)
All-cause death* 223 1.23 (0.88–1.73)
*All-cause death was not a constituent of our composite outcome. H
cardiac arrest, or CHD death. Multivariatemodel was adjusted for age, s
high-density lipoprotein, triglycerides, cigarette smoking, blood pressu
CI  confidence interval; MESA  Multi-Ethnic Study of Atheroscler
Demographic Characteristics of Participants WiWho Did and Did Not Have Diabetes Mellitus DuTable 3 Demograph c Charac ristics of ParWho Did and Did Not Have Diabete
Variables
Diabetes
(n 
Age, yrs 62.1
Male 50
Race/ethnicity
Caucasian 28
Chinese 11
African American 33
Hispanic 27
Systolic BP, mm Hg 131.9
Current/former cigarette smoking 52
Body mass index, kg/m2 31.7
Cholesterol, mg/dl
Total 192.2
LDL 115.6
HDL 46.3
Triglycerides 154.5
Framingham risk score 9.6Values are mean  SD or %.
Abbreviations as in Table 1.ignificantly higher incident CV events compared with
articipant with NFG at baseline who did not have DM
uring follow-up (data not shown).
iscussion
he goal of this study was to evaluate the hypothesis that
FG is an independent risk factor for CV events in a
opulation-based sample of adults free of CVD at baseline.
fter 7.5 years of follow-up of the largest multi-ethnic
ohort so far studied on this subject, we observed that: 1) the
hreshold of fasting blood glucose that is independently
ssociated with CV risk may be in the DM range; 2) IFG is
n independent risk factor for future T2DM; and 3) IFG is
ot an independent CV risk factor. Since T2DM is an
ndependent CV risk factor, aggressive lifestyle modifica-
ions that reduce the incidence of T2DM in persons with
FG may have significant impact on CV events rates in this
opulation.
Withscular Diseasees in the MESA Studye Compar d With
of Cardiovascular Disease
ease Outcomes in the MESA Study
p Value
Multivariate Model
(95% CI) p Value
0.0001 1.16 (0.88–1.52) 0.29
0.04 1.01 (0.72–1.42) 0.97
0.05 1.21 (0.76–1.94) 0.42
0.49 0.85 (0.48–1.51) 0.58
0.0001 1.44 (0.99–2.10) 0.06
0.23 0.95 (0.67–1.35) 0.78
ronary heart disease (CHD): myocardial infarction (MI), resuscitated
/ethnicity, bodymass index, systolic blood pressure, total cholesterol,
ications, and statin use.
paired Fasting GlucoseFollow-Up in the MESA Studyants With Impaired Fasting Glucose
llitus During Follow-Up in the MESA Study
tus No Diabetes
Mellitus (n  600) p Value
65.0 9.6 0.01
59.8 0.01
0.08
32.5
16.0
27.8
23.7
131.5 21.0 0.80
46.7 0.50
29.3 5.1 0.001
196.0 33.8 0.13
119.9 30.3 0.06
47.7 13.1 0.15
143.0 86.4 0.08
10.6 8.6 0.09arediovautcomlu s
come
r Dis
l
ard co
ex, raceth Imringt cip
s Me
Melli
273)
 10.0
.6
.1
.4
.0
.5
 19.2
.8
 6.1
 37.2
 31.8
 11.9
 97.5
 7.9
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July 5, 2011:140–6 IFG, Incident Type 2 DM, and CVD Events in AdultsEven though current theory supports the association be-
tween IFG and incident CV events, the data are mixed (5–15).
Coutinho et al. (10) showed in a meta-analysis of 20 studies
that the progressive relationship between glucose levels and
CV risk extends below the diabetic threshold. Kim et al. (9)
showed in a cross-sectional study that IFG may not be
associated with increased CV risk in community-based sub-
jects. Tominaga et al. (12) used a Japanese population to show
that impaired glucose tolerance was a risk factor for CVD but
IFG was not a risk factor for CVD. Pankow et al. (11) showed
in the ARIC study that in addition to the poor agreement
between IFG and post-challenge glucose levels, neither fasting
glucose nor impaired glucose tolerance was associated with
adverse CV risk profile. Kanaya et al. (7) also showed that IFG
is not independently associated with increased risk of CV
events in post-menopausal women with coronary artery dis-
ease. However, Levitzky et al. (8) used the Framingham
Offspring Study participants to show that IFG may be an
independent CV risk factor in women but not in men. Sawar
et al. (13) added a systematic review of Western cohorts to the
Reykjavik prospective study to show a modest CV risk among
Caucasians with IFG. The findings of this study (13) were also
limited by the incomplete adjustment for confounders in these
studies and the use of ICD-9 codes in the ascertainment of
outcomes. Ford et al. (14) also showed a modest increase CV
risk in their meta-analyses on the association of IFG and CV
outcomes. However, those researchers admitted in their con-
clusions that depending on the set of studies included in their
meta-analysis, their findings could be interpreted as no increase
or at most a very modest increase in CV risk (14). The present
study adds to the data, suggesting that while IFG is a risk
factor for T2DM and DM is an independent CV risk factor,
IFG per se is not an independent CV risk factor, at least during
a relatively short time-frame.
The concept of IFG defined as fasting blood glucose
between 110 and 125 mg/dl was recommended by the
American Diabetes Association Expert Committee in 1997
as a risk category for further screening using a more
definitive test such as a 2-h post-challenge glucose test in
subjects at risk of developing T2DM (19). Data from
population studies suggested that a fasting blood glucose
range of 94 to 103 mg/dl predicted persons in whom
T2DM would develop (20). On the basis of these
population-based studies and in an attempt to increase the
sensitivity of IFG as a screening tool, the fasting glucose
criterion was lowered in 2003 by the American Diabetes
Association to 100 to 125 mg/dl. The implication of the
lowering of the fasting glucose criterion was an almost
quadrupling of the number of Americans with IFG, from 12
million to 44 million (1). The present study found IFG as
an independent risk factor for the development of T2DM,
supporting the notion that interventions aimed at reducing
the incidence of IFG would ultimately result in a reduction
in the incidence of T2DM in the population.
Diabetes mellitus is considered a coronary heart disease
equivalent (11), and persons with IFG (pre-diabetes) havean increased risk of T2DM developing. Supported by a
meta-regression analysis (10), IFG was postulated to be an
independent CV risk factor, and this has been adopted by
the American Diabetes Association. In the present study,
the significant association of IFG and CV events in our
univariate model was explained by traditional CV risk
factors, suggesting that the proposed increased CV risk may
be due to the coexistence of traditional CV risk factors in
persons with IFG.
The subset of IFG subjects in whom T2DM developed
during the follow-up period had similar risk for CV events
compared with subjects with IFG who did not have T2DM
during the follow-up period. The subjects with IFG in
whom T2DM developed during follow-up were younger,
more likely to be female, and obese. Thus, DM was more
likely to develop in young obese females with IFG in this
cohort, and they would, therefore, be at relatively high risk
of future CV events. This finding needs replication in other
cohorts but has major public health implications with regard
to target blood pressure and lipid goals, and cost and
allocation of resources for the prevention and treatment of
CV diseases. More studies aimed at identifying the subset of
subjects with IFG in whom T2DM would develop and who
are therefore at risk of CV events are needed.
Study limitations. The follow-up period was only 7.5
years. We considered defining IFG and DM using a
time-dependent variable approach (updating the status at
each examination); however, we had insufficient incident
CV events/limited follow-up time post-transition to pro-
duce meaningful results. Therefore, we caution readers to
interpret the results of this study within the context of the
duration of follow-up. It is unclear but possible that, given
the strong association between IFG and incident T2DM, a
longer duration of follow-up may reveal a positive associa-
tion between IFG and CVD events. The sample size of the
subjects with IFG was modest. Our investigation of inci-
dent CV in the IFG subgroup was limited by the relatively
short follow-up time for incident CV after conversion to
T2DM. The participants with T2DM had DM for a
variable period before enrollment in the MESA study; thus,
a comparison of the risk of CV in this group versus IFG or
new T2DM is perhaps not a fair comparison to make. Our
study is observational, and although we adjusted for the
known confounders in our models, our results may still be
affected by residual confounding. Finally, we used a
population-based cohort free of clinical CVD at baseline,
and our findings do not apply to populations with clinical
CVD who are at risk for recurrent CVD.
Conclusions
After 7.5 years of follow-up, simply having IFG was not
associated with an increased risk for incident CV events.
More studies aimed at identifying persons with IFG in
whom T2DM would develop, and who are, therefore, at
increased risk of CV events are needed.
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